Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.50 |
| ▸ | BAZ2B | Q9UIF8 | 8/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | BPTF | Q12830 | 1/20 | 0.38 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | PTAFR | P25105 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10143995 | 0.83 | NOTUM (0.52) | NOTUMCYP1A2TDP1KDM4ESMN1; SMN2 | |
| SCHEMBL21255078 | 0.78 | NOTUM (0.43) | NOTUMBAZ2BCYP1A2TDP1LMNA | |
| SCHEMBL10142910 | 0.77 | MAPT (0.39) | MAPTSMN1; SMN2 | |
| SCHEMBL14143466 | 0.75 | NOTUM (0.41) | NOTUMBAZ2BCYP1A2TDP1LMNA | |
| SCHEMBL7379323 | 0.74 | — | — | |
| SCHEMBL2161595 | 0.73 | CYP1A2 (0.50) | NOTUMCYP1A2TDP1KDM4ESMN1; SMN2 | |
| SCHEMBL14818733 | 0.72 | NOTUM (0.38) | NOTUMBAZ2BLMNAMAPTBPTF | |
| SCHEMBL14885088 | 0.72 | NOTUM (0.38) | NOTUMBAZ2BLMNAMAPTBPTF | |
| SCHEMBL19982010 | 0.71 | DPP4 (0.43) | — | |
| SCHEMBL25397767 | 0.70 | NOTUM (0.47) | NOTUMBAZ2BCYP1A2TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022270994-A1 | NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | 한국화학연구원 | 2022-12-29 | — | — | WO | disclosed |
| US-20180036296-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. | 2018-02-08 | — | — | US | disclosed |
| US-9629831-B2 | Benzamides and related inhibitors of factor XA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9629831-B2 | Benzamides and related inhibitors of factor XA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160317511-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-20160317511-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9108922-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108922-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20140377247-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140377247-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20120083602-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. | 2012-04-05 | — | — | US | disclosed |
| US-8063036-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100298284-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-7727982-B2 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7727981-B2 | monoamidino-containing compounds having good bioavailability and/or solubility, used as potent and specific inhibitors of blood coagulation in mammals, and as therapeutic agents for disease states characterized by coagulation disorders | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20090131411-A1 | monoamidino-containing compounds having good bioavailability and/or solubility, used as potent and specific inhibitors of blood coagulation in mammals, and as therapeutic agents for disease states characterized by coagulation disorders | MILLENNIUM PHARMACEUTICALS, INC. | 2009-05-21 | — | — | US | disclosed |
| US-7342013-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-03-11 | — | — | US | disclosed |
| US-7314874-B2 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide;modified amidine elements of high potency in vitro, excellent pharmacological and pharmaceutical properties in vivo | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7285565-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | MILLENNIUM PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131411-A1 | monoamidino-containing compounds having good bioavailability and/or solubility, used as potent and specific inhibitors of blood coagulation in mammals, and as therapeutic agents for disease states characterized by coagulation disorders | F12, F2, PIGS | NOTUM 1458/4885BAZ2B 1189/4885CYP1A2 564/4885 |
| US-20160317511-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | NOTUM 691/4885BAZ2B 82/4885CYP1A2 701/4885 |
| US-20100298284-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | NOTUM 691/4885BAZ2B 82/4885CYP1A2 701/4885 |
| US-20180036296-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | NOTUM 691/4885BAZ2B 82/4885CYP1A2 701/4885 |
| US-20140377247-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | NOTUM 691/4885BAZ2B 82/4885CYP1A2 701/4885 |
| US-20120083602-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | NOTUM 691/4885BAZ2B 82/4885CYP1A2 701/4885 |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | F2, TFPI, PLG | NOTUM 1829/4885BAZ2B 157/4885CYP1A2 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.